Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ZNTL Zentalis Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ZNTL
Price (delayed)
$1.21
Market cap
$87.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.13
Enterprise value
$81.16M
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of
Highlights
The company's debt fell by 9% YoY and by 2.3% QoQ
Zentalis Pharmaceuticals's EPS has decreased by 34% from the previous quarter but it has increased by 6% YoY
ZNTL's gross profit has shrunk by 200% YoY
The revenue has dropped by 200% year-on-year
Key stats
What are the main financial stats of ZNTL
Market
Valuations
Earnings
Shares outstanding
71.95M
Market cap
$87.06M
Enterprise value
$81.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
-$40.56M
Gross profit
-$40.56M
Operating income
-$279.48M
Net income
-$224.19M
EBIT
-$224.15M
EBITDA
-$222.93M
Free cash flow
-$151.63M
Per share
Balance sheet
Liquidity
EPS
-$3.13
EPS diluted
-$3.13
Free cash flow per share
-$2.12
Book value per share
$4.11
Revenue per share
-$0.57
TBVPS
$5.36
Total assets
$384.02M
Total liabilities
$88.64M
Debt
$38.65M
Equity
$295.38M
Working capital
$293.45M
Debt to equity
0.13
Current ratio
6.94
Quick ratio
6.78
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51%
Return on equity
-65.5%
Return on invested capital
-59%
Return on capital employed
-67%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZNTL stock price
How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
-3.2%
1 week
0.83%
1 month
-14.79%
1 year
-89.89%
YTD
-60.07%
QTD
-23.9%
Financial performance
How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
-$40.56M
Gross profit
-$40.56M
Operating income
-$279.48M
Net income
-$224.19M
Gross margin
N/A
Net margin
N/A
ZNTL's gross profit has shrunk by 200% YoY
The revenue has dropped by 200% year-on-year
Zentalis Pharmaceuticals's net income has decreased by 35% from the previous quarter and by 2.4% YoY
The operating income has contracted by 8% from the previous quarter and by 8% YoY
Price vs fundamentals
How does ZNTL's price correlate with its fundamentals
Growth
What is Zentalis Pharmaceuticals's growth rate over time
Valuation
What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Zentalis Pharmaceuticals's EPS has decreased by 34% from the previous quarter but it has increased by 6% YoY
The P/B is 93% less than the 5-year quarterly average of 4.2 and 52% less than the last 4 quarters average of 0.6
ZNTL's equity is down by 36% YoY and by 12% from the previous quarter
The revenue has dropped by 200% year-on-year
Efficiency
How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC has dropped by 51% since the previous quarter and by 20% year-on-year
The ROE has dropped by 51% since the previous quarter and by 42% year-on-year
The ROA is down by 48% since the previous quarter and by 35% year-on-year
Dividends
What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZNTL.
Financial health
How did Zentalis Pharmaceuticals financials performed over time
The total assets has contracted by 31% YoY and by 11% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 24% YoY and by 6% from the previous quarter
The company's debt is 87% lower than its equity
The debt to equity has grown by 44% year-on-year and by 8% since the previous quarter
ZNTL's equity is down by 36% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.